OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
AAYU56

Aayush Wellness Ltd

PharmaceuticalsVerified

Aayush Wellness Limited exhibits a strong capital structure with a debt-to-equity ratio of 0.01, indicating minimal leverage and a conservative financing approach. The company's liquidity position is reflected in a current ratio of 4.0, suggesting ample short-term assets to cover liabilities. However, the risk assessment notes a medium liquidity risk, with net cash being negative after subtracting total debt. In terms of profitability, Aayush Wellness Limited demonstrates a return on equity (ROE) of 0.4065 and a return on assets (ROA) of 0.3893, both of which are strong indicators of efficient capital utilization and asset management. These metrics suggest the company is generating substantial returns relative to its equity and asset base. The company's revenue is primarily concentrated in its core offerings of nutraceuticals, wellness supplements, and lifestyle products, with additional services such as online consultations and diagnostics. There is no detailed breakdown of revenue by geographic region or segment in the provided data, but the company's operations are centered in India. Aayush Wellness Limited's growth trajectory is supported by a positive free cash flow of 33,015,000 INR and a capital expenditure of -687,000 INR, indicating that the company is generating more cash than it is investing in capital assets. The company's operating cash flow of 3,811,000 INR further supports its ability to sustain operations and fund growth. The risk assessment highlights a low dilution risk, with no significant dilution potential identified in the basic shares outstanding. The company's conservative capital structure and strong profitability metrics reduce the likelihood of near-term dilution. However, the risk assessment also notes a medium liquidity risk, primarily due to the negative net cash position after accounting for total debt. Recent events and filings do not provide specific details on recent corporate actions or strategic developments. The company's financial snapshot and valuation metrics suggest a stable and profitable business model, but further information on recent events would be necessary to fully assess its current strategic direction.

30-day price · AAYU+4.01 (+13.8%)
Low$27.80High$41.49Close$33.08As of15 May, 00:00 UTC
Profile
CompanyAayush Wellness Ltd
TickerAAYU.BO
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Aayush Wellness Limited is an India-based integrated healthcare company that produces, markets, and distributes health and wellness products, including nutraceuticals, wellness supplements, and lifestyle products, and offers digital health services such as online consultations and diagnostics.

Classification. Aayush Wellness Limited is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a high confidence level of 0.92.

Aayush Wellness Limited exhibits a strong capital structure with a debt-to-equity ratio of 0.01, indicating minimal leverage and a conservative financing approach. The company's liquidity position is reflected in a current ratio of 4.0, suggesting ample short-term assets to cover liabilities. However, the risk assessment notes a medium liquidity risk, with net cash being negative after subtracting total debt. In terms of profitability, Aayush Wellness Limited demonstrates a return on equity (ROE) of 0.4065 and a return on assets (ROA) of 0.3893, both of which are strong indicators of efficient capital utilization and asset management. These metrics suggest the company is generating substantial returns relative to its equity and asset base. The company's revenue is primarily concentrated in its core offerings of nutraceuticals, wellness supplements, and lifestyle products, with additional services such as online consultations and diagnostics. There is no detailed breakdown of revenue by geographic region or segment in the provided data, but the company's operations are centered in India. Aayush Wellness Limited's growth trajectory is supported by a positive free cash flow of 33,015,000 INR and a capital expenditure of -687,000 INR, indicating that the company is generating more cash than it is investing in capital assets. The company's operating cash flow of 3,811,000 INR further supports its ability to sustain operations and fund growth. The risk assessment highlights a low dilution risk, with no significant dilution potential identified in the basic shares outstanding. The company's conservative capital structure and strong profitability metrics reduce the likelihood of near-term dilution. However, the risk assessment also notes a medium liquidity risk, primarily due to the negative net cash position after accounting for total debt. Recent events and filings do not provide specific details on recent corporate actions or strategic developments. The company's financial snapshot and valuation metrics suggest a stable and profitable business model, but further information on recent events would be necessary to fully assess its current strategic direction.
Key takeaways
  • Aayush Wellness Limited has a strong return on equity (ROE) of 0.4065 and a return on assets (ROA) of 0.3893, indicating efficient capital and asset utilization.
  • The company maintains a conservative capital structure with a debt-to-equity ratio of 0.01 and a current ratio of 4.0, suggesting strong liquidity and minimal leverage.
  • Aayush Wellness Limited generates a positive free cash flow of 33,015,000 INR, supporting its ability to sustain operations and fund growth.
  • The company's risk assessment indicates a low dilution risk and a medium liquidity risk, primarily due to a negative net cash position after accounting for total debt.
  • The company's operations are centered in India, with a focus on nutraceuticals, wellness supplements, and lifestyle products, along with digital health services.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$733.5M
Gross profit$44.8M
Operating income$33.4M
Net income$33.7M
R&D
SG&A
D&A
SBC
Operating cash flow$3.8M
CapEx-$687.0k
Free cash flow$33.0M
Total assets$86.5M
Total liabilities$3.7M
Total equity$82.8M
Cash & equivalents
Long-term debt$453.0k
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$82.8M
Net cash-$453.0k
Current ratio4.0
Debt/Equity0.0
ROA38.9%
ROE40.6%
Cash conversion11.0%
CapEx/Revenue-0.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 1 companies
MetricAAYUActivity
Op margin4.5%-2.9% medp25 -218.9% · p75 9.6%above median
Net margin4.6%28.2% medp25 28.2% · p75 28.2%bottom quartile
Gross margin6.1%47.8% medp25 27.6% · p75 68.9%bottom quartile
CapEx / revenue-0.1%6.6% medp25 6.6% · p75 6.6%bottom quartile
Debt / equity1.0%271.5% medp25 271.5% · p75 271.5%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 09:03 UTC#a45dee6f
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 09:04 UTCJob: 66200bd9